[
    [
        {
            "time": "2018-03-15",
            "original_text": "Agree To Purchase AbbVie At $55, Earn 3.2% Using Options",
            "features": {
                "keywords": [
                    "Purchase",
                    "AbbVie",
                    "Options"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Agree To Purchase AbbVie At $55, Earn 3.2% Using Options",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual 'Week of Possibilities'",
            "features": {
                "keywords": [
                    "Employees",
                    "Volunteer",
                    "Week of Possibilities"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual 'Week of Possibilities'",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-06-22",
            "original_text": "Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Phase-3",
                    "MURANO",
                    "Trial",
                    "Venetoclax",
                    "Rituximab"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-10",
            "original_text": "3 Great Reasons to Buy Gilead Sciences",
            "features": {
                "keywords": [
                    "Gilead",
                    "Sciences",
                    "Buy"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "3 Great Reasons to Buy Gilead Sciences",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-15",
            "original_text": "Bristol-Myers Posts Data on Empliciti, China Approves Opdivo",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Empliciti",
                    "Opdivo",
                    "China",
                    "Approves"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Bristol-Myers Posts Data on Empliciti, China Approves Opdivo",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]